Linafexor

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLinafexor
Drug Alias NameCS-0159
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBile acid receptor FXR agonists
TargetsBile acid receptor FXR
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseInflammatory Bowel DiseasesCholangitis, Sclerosing +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesCascade Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCascade Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseInflammatory Bowel DiseasesCholangitis, Sclerosing +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A